Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Definiens Closes €10 Million Round to Grow its Clinical Digital Pathology Business

Published: Tuesday, October 02, 2012
Last Updated: Tuesday, October 02, 2012
Bookmark and Share
The financing was led by new investor Gilde Healthcare Partners, a transatlantic investment firm with €450 million under management, focusing on the private healthcare sector.

Existing investors, including TVM, Cipio and Definiens’ management also participated in the financing round.

Definiens will primarily use the funding for commercial expansion of its current business and to develop and commercialize innovative products for Clinical Digital Pathology. The company’s solutions are currently being used for research and development by all major pharmaceutical companies as well as an increasing number of diagnostic companies in tissue based diagnostic biomarker development.

Dr Janke Dittmer, partner at Gilde Healthcare Partners, has joined the Company’s Supervisory Board.

“This new round of funding allows Definiens’ to grow its Clinical Digital Pathology business,” said Thomas Heydler, CEO of Definiens. “Gilde Healthcare Partners joins our team of committed investors. With their financial support and partnership, we will build on the success of our existing business and increase our presence in the clinical routine use of Digital Pathology.”

“Digital Pathology combined with the right image analysis tools has the potential to transform cancer diagnosis. As the market leader in image analysis for Digital Pathology Definiens is well positioned to unlock the full potential of tissue based diagnostics and drive the clinical adoption of quantitative Digital Pathology.” said Janke Dittmer. “We led this investment round because we believe that Definiens has a set of market leading products, a strong patent portfolio and unique capabilities to turn new concepts into clinically relevant products which will benefit people suffering from cancer around the world.”

Definiens’ proprietary Cognition Network Technology® enables best in class analysis of Digital Pathology images, but can also be used on other types of images. It is the brainchild of Definiens' founder, CTO and Nobel Laureate Prof Dr Gerd Binnig. Its context based segmentation approach leads to unsurpassed accuracy in detecting structures of interest and is robust with regard to variations in the tissue and the scanner used.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Definiens Secures € 15 Million for Tissue Phenomics-based Cancer Diagnostics
Big data approach bridges the gap between genomics and personalized medicine.
Saturday, June 28, 2014
Definiens Expands Management Team to Develop the Clinical Market
Company announces appointment of Pablo Jordan and Rebecca Berghorn.
Tuesday, October 29, 2013
Definiens Appoints Chief Marketing Officer, Merrilyn Datta, Ph.D.
Dr. Datta brings a wealth of experience in marketing and her expertise will be critical as Definiens expands its leadership in the life sciences and tissue diagnostics industries.
Tuesday, April 09, 2013
Definiens Establishes Advisory Board
Renowned industry experts to advise Definiens on clinical digital pathology market.
Thursday, March 28, 2013
Definiens Appoints Dr. Gerald Möller as Chairman of its Supervisory Board
Definiens AG announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman.
Thursday, November 15, 2012
Scientific News
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
New Test Detects All Viruses
A new test detects virtually any virus that infects people and animals, according to research at Washington University School of Medicine in St. Louis, where the technology was developed.
Scientists Create World’s Largest Catalog of Human Genomic Variation
An international team of scientists from the 1000 Genomes Project Consortium has created the world’s largest catalog of genomic differences among humans, providing researchers with powerful clues to help them establish why some people are susceptible to various diseases.
Chip-Based Technology Enables Reliable Direct Detection of Ebola Virus
Hybrid device integrates a microfluidic chip for sample preparation and an optofluidic chip for optical detection of individual molecules of viral RNA.
Diagnostics Breakthrough Brings Viral Sequencing to Doctors’ Toolkit
New screening tool produces up to 10,000-fold improvement in viral matches compared with traditional high-throughput methods.
New Cell Type May Help Explain Dangerous Food Allergies
Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.
Molecular Diagnostics At Home
Electrochemical test's sensing principle may be generalized to many different targets, leading to inexpensive devices that could detect dozens of disease markers in less than 5 minutes.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos